LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

4.42 -0.67

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.4

Максимум

4.49

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	14M 35M
Предишно отваряне	5.09
Предишно затваряне	4.42

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.02.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22.02.2026 г., 23:21 ч. UTC

Печалби

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22.02.2026 г., 23:20 ч. UTC

Печалби

Nickel Industries 2025 Operating Profit US$126.4 Million

22.02.2026 г., 23:19 ч. UTC

Печалби

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22.02.2026 г., 23:19 ч. UTC

Печалби

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22.02.2026 г., 23:18 ч. UTC

Печалби

Nickel Industries Won't Pay a Final Dividend

22.02.2026 г., 23:16 ч. UTC

Печалби

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22.02.2026 г., 21:35 ч. UTC

Печалби

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol Final Dividend A$0.60/Share

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Revenue A$31.37 Billion, Down 10%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21.02.2026 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.